433 related articles for article (PubMed ID: 33035446)
1. Antisense Drugs Make Sense for Neurological Diseases.
Bennett CF; Kordasiewicz HB; Cleveland DW
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
Bennett CF; Krainer AR; Cleveland DW
Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
5. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
8. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides: treating neurodegeneration at the level of RNA.
DeVos SL; Miller TM
Neurotherapeutics; 2013 Jul; 10(3):486-97. PubMed ID: 23686823
[TBL] [Abstract][Full Text] [Related]
12. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
13. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
14. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases.
Wu P; Zuo X; Deng H; Liu X; Liu L; Ji A
Brain Res Bull; 2013 Aug; 97():69-80. PubMed ID: 23756188
[TBL] [Abstract][Full Text] [Related]
15. Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases.
Romano R; Bucci C
Neural Regen Res; 2024 May; 19(5):1027-1035. PubMed ID: 37862205
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets.
Klim JR; Vance C; Scotter EL
Int J Biochem Cell Biol; 2019 May; 110():149-153. PubMed ID: 30904737
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
19. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.
Jablonka S; Hennlein L; Sendtner M
Neurol Res Pract; 2022 Jan; 4(1):2. PubMed ID: 34983696
[TBL] [Abstract][Full Text] [Related]
20. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]